Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…The NIC-PD-study –Baseline data of a randomized, placebo-controlled, double-blind, multi-centre trial to assess the disease-modifying potential of transdermal nicotine in early Parkinson’s disease in Germany and the USA
Objective: The primary endpoint of clinical progression is measured by change in the total UPDRS score between baseline and 1) after 52 weeks of study…Apomorphine treatment in advanced Parkinson’s disease (PD): Duration of treatment and safety experience in a managed care program in Germany
Objective: To evaluate the duration of treatment (DOT) and safety of apomorphine continuous subcutaneous infusion (CSI) in patients with advanced PD inscribed in a managed…Histology of subcutaneous nodules in PD patients treated with continuous apomorphine infusion: Case series and review of the literature
Objective: To examine the histology of subcutaneous nodules after continuous subcutaneous apomorphine infusion (CSAI). Background: CSAI has been used successfully in advanced Parkinson's disease (PD).…Levodopa/carbidopa intestinal gel treatment in advanced Parkinson’s disease: A long-term observational study
Objective: To evaluate long-term efficacy, levodopa dose changes and complications in patients with advanced Parkinson's disease (PD) treated. Background: Administrated via percutaneous gastric gastrostomy to…Subthalamic deep brain stimulation vs. intraduodenal levodopa infusion: A long-term retrospective comparative study
Objective: To analyze the long-term retrospective data of patients treated with Levodopa/carbidopa intestinal gel infusion (LCIG) and subthalamic nucleus deep brain stimulation (STN-DBS) in two…A multi-centre European comparative survey of advanced therapies (infusion and deep brain stimulation) in Parkinson’s disease
Objective: To address comparative demographic and other variables for Parkinson's disease patients at baseline for infusion therapies (subcutaneous apomorphine (Apo), intrajejunal levodopa (IJLI)) and deep…Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…Effects of plantar automated mechanical stimulation (AMPS) on motor symptoms of patients with advanced Parkinson’s disease: Preliminary data of a double blind randomized clinical trial
Objective: To evaluate the effect of one session treatment with autometed mechanical peripheral stimulation (AMPS) on gait and motor functions of patients with advanced Parkinson's…Clinical and biological predictors of time to initiation of symptomatic therapy in early Parkinson’s disease
Objective: To determine clinical and biological variables that predict time to initiation of symptomatic therapy (TIST) in de novo Parkinson's disease (PD) patients. Background: There…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.